PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteLight can trigger drug release by removing a temporary chemical mask from a drug or by changing how a carrier lets molecules pass through it. A 2007 laboratory study showed one version: 365 nm light released aspirin, ibuprofen and ketoprofen from polymer scaffolds in controlled, stepped doses. That demonstrated a materials and photochemistry concept—not a treatment validated in patients.
How does light-triggered drug release work?
In a photocaged-drug approach, a light-sensitive chemical group is attached to a drug, temporarily preventing it from acting in its usual way. When the relevant light reaches the molecule, it cleaves away the group and frees the drug. Controlling where and when illumination is applied can, in principle, control where and when release occurs.
As an Amazon Associate I earn from qualifying purchases.
This is not the only way light can influence delivery. Some systems use illumination to change a carrier’s structure or transport properties; phototherapy instead uses light to activate or enable a therapeutic effect. Those mechanisms are related by their use of light, but they are not interchangeable.
What did the 2007 experiment demonstrate?
McCoy and colleagues attached a 3,5-dimethoxybenzoin photolabile group to acetyl salicylic acid (aspirin), ibuprofen and ketoprofen. The conjugates responded to 365 nm light. The team incorporated them into limited-porosity hydrogel scaffolds made from hydrated 2-hydroxyethyl methacrylate and methyl methacrylate copolymer, crosslinked with ethylene glycol dimethacrylate. The primary paper reports that irradiation time controlled release and demonstrates stepped doses from the scaffolds.
#1 Best Overall
The paper, “Light-Triggered Molecule-Scale Drug Dosing Devices,” was published online July 18, 2007, and appeared in a Journal of the American Chemical Society issue dated August 8, 2007. Its abstract describes “a paradigm for the controlled, light-triggered release of ‘stepped’ doses of drugs from polymeric scaffolds.” This is a bench-scale demonstration of photochemistry and material behavior, not evidence that the system was tested as a clinical treatment or shown safe and effective in people.
How does this differ from other light-responsive systems?
| Approach | What light does | Evidence described in the cited sources |
|---|---|---|
| Photocaged drug in a scaffold | Cleaves a photolabile group to free the drug; in the 2007 study, irradiation time controlled release. | Laboratory demonstration using 365 nm light and drug-loaded polymer scaffolds. McCoy et al., 2007. |
| Light-responsive membrane or carrier | Changes material structure or transport properties, rather than necessarily uncaging a drug. | A 2022 report described light-induced ion transport through a synthetic conjugated microporous polymer membrane. Drug-release vehicles were presented as a possible future application, not a demonstrated therapeutic outcome. Nature Middle East, 2022. |
| Phototherapy | Uses light to activate or enable a therapeutic effect; it is not synonymous with drug release. | A 2023 review discusses approaches and translation barriers, including light access and suitable photolabile groups for some photoactivated chemotherapy strategies. Angewandte Chemie International Edition, 2023. |
Why is the light source a major practical constraint?
The 2007 system used 365 nm ultraviolet light in a laboratory. Applying a light-controlled concept inside the body requires getting light to the intended target and selecting chemistry that can be activated under conditions compatible with biological tissue. A result at one wavelength in a material experiment does not establish that the same design can work at a deep or dispersed site in a patient.
Rank #2
- Convenient Documentation Storage - Makes it easy to comply with audits and regulations like 21 U.S.C. 827 (b), 21 U.S.C. 827 (c)-DEA, and 42 CFR 483.60-CMS
- All Your Documentation in One Place - Makes it easy to track things like intake and usage; keep your records together for DEA audits
- Controlled Substance Logging - Makes it easy to track drugs intake and expenditure; helps track things like loss and destruction
- High Page Count Makes Tracking Easy - Makes it easy to track prescriptions and narcotics during the entire retention period
- Great for Tracking - Schedule 2 intakes from the pharmacy, narcotic emergency drug kit usage, and the count of narcotic emergency drug kits at the beginning and end of each shift
A 2023 review of photoactivated chemotherapy identifies a shortage of suitably hydrophilic photolabile protecting groups that can be activated by biologically benign red or near-infrared light as one barrier to clinical translation. It also discusses difficulties treating dispersed or diffuse tumor cells with localized phototherapies. These are challenges described for the approaches covered by that review, not a universal verdict on every light-responsive delivery platform.
What medical uses were proposed, and what is established?
A 2007 Chemistry World account discussed possible medical-device applications, including infection control on catheters and intratracheal tubes, and the idea of delivering light to a target through a fibre-optic wire. Those were potential uses discussed at the time, not proof that the scaffold became a clinical product or prevented infections in patients. The report also explains the researchers’ rationale for immobilizing the masked drug in a polymer: they did not want the drug-and-protecting-group conjugate circulating through the body after release.
Rank #3
For the specific 2007 system, the evidence supports controlled release in a laboratory scaffold and a proposed device concept. It does not establish clinical safety, efficacy, or patient benefit. The 2022 membrane report likewise describes ion transport and a possible future drug-release application, rather than a proven treatment.
Quick Recap
Best Value
Rank #4
- New
- Mint Condition
- Dispatch same day for order received before 12 noon
- Guaranteed packaging
- No quibbles returns
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
